Shares fell more than 8% in premarket trading. The company said it was halting the development program in light of disappointing preclinical studies. Shares fell more than 8% in premarket trading. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果